ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial

Liu, Meifang; Di, Yuan Ming; Zhang, Lei; Yang, Lihong; Zhang, La; Chen, Junhui; Wang, Ruobing; Xie, Xiaoning; Lan, Fang; Xie, Liping; Huang, Juan; Zhang, Anthony Lin; Xue, Charlie Changli*; Liu, Xusheng*广东省人民医院; 广州中医药大学; 1
Frontiers in Endocrinology2024-2-8DOI: 10.3389/fendo.2024.1334609
19阅读
引用收藏
分享

摘要

Background: Diabetic kidney disease (DKD) has become the leading cause of kidney failure, causing a significant socioeconomic burden worldwide. The usual care for DKD fails to achieve satisfactory effects in delaying the persistent loss of renal function. A Chinese herbal medicine, Tangshen Qushi Formula (TQF), showed preliminary clinical benefits with a sound safety profile for people with stage 2-4 DKD. We present the protocol of an ongoing clinical trial investigating the feasibility, efficacy, and safety of TQF compared to placebo in delaying the progressive decline of renal function for people with stage 2-4 DKD. Methods: A mixed methods research design will be used in this study. A randomized, double-blind, placebo-controlled pilot trial will evaluate the feasibility, efficacy, and safety of TQF compared to placebo on kidney function for people with stage 2-4 DKD. An embedded semi-structured interview will explore the acceptability of TQF granules and trial procedures from the participant's perspective. Sixty eligible participants with stage 2-4 DKD will be randomly allocated to the treatment group (TQF plus usual care) or the control group (TQF placebo plus usual care) at a 1:1 ratio for 48-week treatment and 12-week follow-up. Participants will be assessed every 12 weeks. The feasibility will be assessed as the primary outcome. The changes in the estimated glomerular filtration rate, urinary protein/albumin, renal function, glycemic and lipid markers, renal composite endpoint events, and dampness syndrome of Chinese medicine will be assessed as the efficacy outcomes. Safety outcomes such as liver function, serum potassium, and adverse events will also be evaluated. The data and safety monitoring board will be responsible for the participants' benefits, the data's credibility, and the results' validity. The intent-to-treat and per-protocol analysis will be performed as the primary statistical strategy. Discussion: Conducting a rigorously designed pilot trial will be a significant step toward establishing the feasibility and acceptability of TQF and trial design. The study will also provide critical information for future full-scale trial design to further generate new evidence supporting clinical practice for people with stage 2-4 DKD.

学科与关键词

关键词
Chinese herbal medicineTangshen Qushi Formuladiabetic kidney diseaserandomized controlled trialsemi-structured interviewfeasibilityefficacysafety
相关
加载中…
  • Renal-protective effects of Chinese medicinal herbs and compounds for diabetic kidney disease in animal models: protocol for systematic review and meta-analysis
    Liu, Meifang; Di, Yuan Ming; Zhang, Anthony Lin; Chen, Junhui; Wang, Ruobing; Huang, Juan; Zhang, Lei; Xue, Charlie Changli*; Liu, Xusheng*Systematic Reviews, 2024, 13(1): 23.
  • Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease
    Mao Wei; Zhang Lei; Zou Chuan; Li Chuang; Wu Yifan; Su Guobin; Guo Xinfeng; Wu Yuchi; Lu Fuhua; Lin Qizhan; Wang Lixin; Bao Kun; Xu Peng; Zhao Daixin; Peng Yu; Liang Hui; Lu Zhaoyu; Gao Yanxiang; Jie Xina; Zhang La; Wen Zehuai*; Liu XushengBMC Complementary and Alternative Medicine, 2015, 15: 316.
  • Evaluation of Renal Impairment in Patients with Diabetic Kidney Disease by Integrated Chinese and Western Medicine
    Qu, Yi-lun; Dong, Zhe-yi; Cheng, Hai-mei; Liu, Qian; Wang, Qian; Yang, Hong-tao; Mao, Yong-hui; Li, Ji-jun; Liu, Hong-fang; Geng, Yan-qiu; Huang, Wen; Liu, Wen-hu; Xie, Hui-di; Peng, Fei; Li, Shuang; Jiang, Shuang-shuang; Li, Wei-zhen; Duan, Shu-wei; Feng, Zhe; Zhang, Wei-guang; Liu, Yu-ning; Tian, Jin-zhou; Chen, Xiang-mei*Chinese Journal of Integrative Medicine, 2023, 29(4): 308-315.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2024-02-08
卷期
第 15 卷
页码
1334609
DOI
10.3389/fendo.2024.1334609
成果收录
SCIE
资助标注
RMIT PhD scholarship; China-Australia International Research Centre for Chinese Medicine; State Key Laboratory of Dampness Syndrome of Chinese Medicine in Guangdong Provincial Hospital of Chinese Medicine [SZ2021ZZ43]; Guangzhou Science and Technology Project [202206010076]; National Natural Science Foundation of China [82004206]

作者

  • L

    Liu, Meifang (第一作者)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • D

    Di, Yuan Ming

查看全部 14 位作者收起作者
  • Z

    Zhang, Lei

  • Y

    Yang, Lihong

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zhang, La

  • C

    Chen, Junhui

    guangzhou univ chinese med

  • W

    Wang, Ruobing

    2 · guangdong prov hosp · guangzhou univ chinese med

  • X

    Xie, Xiaoning

    2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Lan, Fang

    1 · guangxi univ chinese med

  • X

    Xie, Liping

    1 · guangxi univ chinese med

  • H

    Huang, Juan

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zhang, Anthony Lin

  • X

    Xue, Charlie Changli (通讯)

  • L

    Liu, Xusheng (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417